人呼吸道合胞病毒(human respiratory syncytial virus, HRSV)是導(dǎo)致嬰幼兒和老年人下呼吸道感染的主要病原體,給世界各國(guó)公共衛(wèi)生安全造成了極大的威脅。

貨號(hào)：VVV02801

產(chǎn)品鏈接：http://www.antibodysystem.com/product/13698.html

寄主物種：Human

物種反應(yīng)性：Human respiratory syncytial virus (HRSV)

形式：Liquid

存儲(chǔ)緩沖區(qū)：0.01M PBS, pH 7.4.

濃度：1 mg/ml

純度：>95% by SDS-PAGE.

克隆性：Monoclonal

應(yīng)用：ELISA, In vivo Neutralization

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn)：

A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. PMID: 24864121
Rapid Biosensor of SARS-CoV-2 Using Specific Monoclonal Antibodies Recognizing Conserved Nucleocapsid Protein Epitopes. PMID: 35215848
Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PMID: 27611367
Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies. PMID: 32759319

Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. PMID: 16690930
Gene junction sequences of bovine respiratory syncytial virus. PMID: 1626423

福爾馬林滅活HRSV疫苗(formalin-inactivated HRSV vaccine, FI-HRSV)臨床試驗(yàn)的失敗表明HRSV疫苗研發(fā)存在多重難以克服的技術(shù)困難,此后該疫苗的研發(fā)進(jìn)展極其緩慢。近年來(lái),HRSV蛋白結(jié)構(gòu)的深入解析為HRSV疫苗研發(fā)提供了新靶點(diǎn),使HRSV疫苗的研發(fā)策略迅速增多,許多HRSV疫苗相繼進(jìn)入關(guān)鍵性研究階段。目前,全球有19種HRSV疫苗正在開(kāi)展臨床試驗(yàn),還有許多不同類型的候選疫苗也正在進(jìn)行臨床前的測(cè)試。

HRSV屬于肺炎病毒科，正肺病毒屬，有包膜，是非節(jié)段性、單股負(fù)鏈RNA病毒，病毒形狀呈圓形和絲狀體2種，外膜有突起，大小為80 nm至幾μm。HRSV只有1個(gè)血清型，根據(jù)抗原性分為兩大亞型：A型和B型，不同亞型的主要結(jié)構(gòu)蛋白有明顯差異。HRSV無(wú)血凝素和神經(jīng)氨酸酶，未發(fā)現(xiàn)溶血活性。HRSV很不穩(wěn)定，乙醚、氯仿、0.25%胰酶、0.1%去氧膽酸鈉等都能將其滅活。對(duì)熱敏感，55 ℃、5 min可使90%病毒滅活。在pH≤3的酸性環(huán)境中很快被滅活，pH>4以上相對(duì)穩(wěn)定。